+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Anticonvulsants Market Research Report by Drug types (AMPA, Barbiturate, and Benzodiazepine), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 252 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 5305569
UP TO OFF until Dec 31st 2022
The Global Anticonvulsants Market size was estimated at USD 10.22 billion in 2021, USD 11.08 billion in 2022, and is projected to grow at a CAGR 8.60% to reach USD 16.78 billion by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Anticonvulsants to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug types, the market was studied across AMPA, Barbiturate, Benzodiazepine, Carbamate Anticonvulsants, Carbonic Anhydrase Inhibitor, Dibenzazepine, and Triazine.
  • Based on Application, the market was studied across Anxiety, Bipolar Disorder, Borderline Personality Disorder., Epilepsy, Fibromyalgia, Migraine, and Neuropathic Pain.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anticonvulsants market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anticonvulsants Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anticonvulsants Market, including Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Eisai Co., Ltd. by Royalty Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., GW Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lundbeck A/S, Mankind Pharma Ltd, Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical, Pfizer Inc., Sanofi S.A, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Anticonvulsants Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anticonvulsants Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anticonvulsants Market?
4. What is the competitive strategic window for opportunities in the Global Anticonvulsants Market?
5. What are the technology trends and regulatory frameworks in the Global Anticonvulsants Market?
6. What is the market share of the leading vendors in the Global Anticonvulsants Market?
7. What modes and strategic moves are considered suitable for entering the Global Anticonvulsants Market?
Frequently Asked Questions about the Global Anticonvulsants Market

What is the estimated value of the Global Anticonvulsants Market?

The Global Anticonvulsants Market was estimated to be valued at $10.22 Billion in 2021.

What is the growth rate of the Global Anticonvulsants Market?

The growth rate of the Global Anticonvulsants Market is 8.6%, with an estimated value of $16.78 Billion by 2027.

What is the forecasted size of the Global Anticonvulsants Market?

The Global Anticonvulsants Market is estimated to be worth $16.78 Billion by 2027.

Who are the key companies in the Global Anticonvulsants Market?

Key companies in the Global Anticonvulsants Market include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Eisai Co., Ltd. by Royalty Pharma, GlaxoSmithKline PLC and GW Pharmaceuticals PLC.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalences of epilepsy
5.1.1.2. Rising investment and support from the government
5.1.2. Restraints
5.1.2.1. Patent expiration of the second-generation drugs
5.1.2.2. Availability of substitutes options for pain management
5.1.3. Opportunities
5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
5.1.4. Challenges
5.1.4.1. Steep rise in medicine supply shortage for patients
5.2. Cumulative Impact of COVID-19
6. Anticonvulsants Market, by Drug types
6.1. Introduction
6.2. AMPA
6.3. Barbiturate
6.4. Benzodiazepine
6.5. Carbamate Anticonvulsants
6.6. Carbonic Anhydrase Inhibitor
6.7. Dibenzazepine
6.8. Triazine
7. Anticonvulsants Market, by Application
7.1. Introduction
7.2. Anxiety
7.3. Bipolar Disorder
7.4. Borderline Personality Disorder.
7.5. Epilepsy
7.6. Fibromyalgia
7.7. Migraine
7.8. Neuropathic Pain
8. Americas Anticonvulsants Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Anticonvulsants Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Anticonvulsants Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories
12.2. Astrazeneca PLC
12.3. Bausch Health Companies Inc.
12.4. Biocon Limited
12.5. Cadila Pharmaceuticals Limited
12.6. Cipla, Inc.
12.7. Eisai Co., Ltd. by Royalty Pharma
12.8. GlaxoSmithKline PLC
12.9. Glenmark Pharmaceuticals Ltd.
12.10. GW Pharmaceuticals PLC
12.11. Johnson & Johnson Services, Inc.
12.12. Lundbeck A/S
12.13. Mankind Pharma Ltd
12.14. Merck KGaA
12.15. Novartis AG
12.16. Novo Nordisk A/S
12.17. Otsuka Pharmaceutical
12.18. Pfizer Inc.
12.19. Sanofi S.A
12.20. Sunovion Pharmaceuticals Inc.
12.21. Takeda Pharmaceutical Company Limited
12.22. Teva Pharmaceutical Industries Ltd.
12.23. Wockhardt Limited
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ANTICONVULSANTS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ANTICONVULSANTS MARKET SIZE, 2021 VS 2027 (USD BILLION)
FIGURE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL ANTICONVULSANTS MARKET DYNAMICS
FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2021 VS 2027 (%)
FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2021 VS 2027 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2027
FIGURE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, 2019-2027 (USD BILLION)
FIGURE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, 2019-2027 (USD BILLION)
FIGURE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, 2019-2027 (USD BILLION)
FIGURE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 23. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, 2019-2027 (USD BILLION)
FIGURE 24. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 26. GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 27. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2027
FIGURE 28. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, 2019-2027 (USD BILLION)
FIGURE 29. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 30. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2019-2027 (USD BILLION)
FIGURE 31. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 32. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., 2019-2027 (USD BILLION)
FIGURE 33. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 34. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2019-2027 (USD BILLION)
FIGURE 35. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 36. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, 2019-2027 (USD BILLION)
FIGURE 37. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 38. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, 2019-2027 (USD BILLION)
FIGURE 39. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 40. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2019-2027 (USD BILLION)
FIGURE 41. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 42. AMERICAS ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 44. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2027
FIGURE 46. ARGENTINA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. BRAZIL ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. CANADA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. MEXICO ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. UNITED STATES ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 52. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 53. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2027
FIGURE 54. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 56. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2027
FIGURE 58. AUSTRALIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. CHINA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. INDIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. INDONESIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. JAPAN ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. MALAYSIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. PHILIPPINES ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. SINGAPORE ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 66. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 67. TAIWAN ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 68. THAILAND ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 69. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 70. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 71. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 72. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2027
FIGURE 73. FRANCE ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 74. GERMANY ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 75. ITALY ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 76. NETHERLANDS ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 77. QATAR ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 78. RUSSIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 79. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 80. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 81. SPAIN ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 82. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 83. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 84. GLOBAL ANTICONVULSANTS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 85. GLOBAL ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 86. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTICONVULSANTS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2019-2027 (USD BILLION)
TABLE 7. AMERICAS ANTICONVULSANTS MARKET SIZE, BY AMPA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY AMPA, BY STATE, 2019-2027 (USD BILLION)
TABLE 9. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY AMPA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY AMPA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2019-2027 (USD BILLION)
TABLE 12. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY STATE, 2019-2027 (USD BILLION)
TABLE 14. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 17. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 19. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2019-2027 (USD BILLION)
TABLE 22. AMERICAS ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY STATE, 2019-2027 (USD BILLION)
TABLE 24. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 27. AMERICAS ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 29. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 31. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 32. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 33. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 34. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 36. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 37. AMERICAS ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 38. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 39. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 42. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2019-2027 (USD BILLION)
TABLE 43. AMERICAS ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY STATE, 2019-2027 (USD BILLION)
TABLE 45. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 47. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2019-2027 (USD BILLION)
TABLE 48. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY STATE, 2019-2027 (USD BILLION)
TABLE 50. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 52. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY REGION, 2019-2027 (USD BILLION)
TABLE 53. AMERICAS ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 54. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY STATE, 2019-2027 (USD BILLION)
TABLE 55. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 57. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2019-2027 (USD BILLION)
TABLE 58. AMERICAS ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 59. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY STATE, 2019-2027 (USD BILLION)
TABLE 60. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 62. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2019-2027 (USD BILLION)
TABLE 63. AMERICAS ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 64. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY STATE, 2019-2027 (USD BILLION)
TABLE 65. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 67. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 68. AMERICAS ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 69. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 70. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 72. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2019-2027 (USD BILLION)
TABLE 73. AMERICAS ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 74. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY STATE, 2019-2027 (USD BILLION)
TABLE 75. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 77. AMERICAS ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 78. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 79. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 80. AMERICAS ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 81. ARGENTINA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 83. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 84. BRAZIL ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 86. BRAZIL ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 87. CANADA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 88. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 89. CANADA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 90. MEXICO ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 91. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 92. MEXICO ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 93. UNITED STATES ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 94. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2019-2027 (USD BILLION)
TABLE 95. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 96. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 97. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 98. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 99. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 100. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 101. AUSTRALIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 102. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 103. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 104. CHINA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 105. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 106. CHINA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 107. INDIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 108. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 109. INDIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 110. INDONESIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 111. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 112. INDONESIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 113. JAPAN ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 114. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 115. JAPAN ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 116. MALAYSIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 117. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 118. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 119. PHILIPPINES ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 120. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 121. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 122. SINGAPORE ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 123. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 124. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 125. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 126. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 127. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 128. TAIWAN ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 129. TAIWAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 130. TAIWAN ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 131. THAILAND ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 132. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 133. THAILAND ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 138. FRANCE ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 139. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 140. FRANCE ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 141. GERMANY ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 142. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 143. GERMANY ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 144. ITALY ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 145. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 146. ITALY ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 147. NETHERLANDS ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 148. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 149. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 150. QATAR ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 151. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 152. QATAR ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 153. RUSSIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 154. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 155. RUSSIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 156. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 157. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 158. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 159. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 160. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 161. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 162. SPAIN ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 163. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 164. SPAIN ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 165. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 166. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 167. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 168. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 169. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2019-2027 (USD BILLION)
TABLE 170. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 171. GLOBAL ANTICONVULSANTS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 172. GLOBAL ANTICONVULSANTS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 173. GLOBAL ANTICONVULSANTS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 174. GLOBAL ANTICONVULSANTS MARKET RANKING
TABLE 175. GLOBAL ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 176. GLOBAL ANTICONVULSANTS MARKET MERGER & ACQUISITION
TABLE 177. GLOBAL ANTICONVULSANTS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 178. GLOBAL ANTICONVULSANTS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 179. GLOBAL ANTICONVULSANTS MARKET INVESTMENT & FUNDING
TABLE 180. GLOBAL ANTICONVULSANTS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 181. GLOBAL ANTICONVULSANTS MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Astrazeneca PLC
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Eisai Co., Ltd. by Royalty Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • GW Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Mankind Pharma Ltd
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical
  • Pfizer Inc.
  • Sanofi S.A
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited

Methodology

Loading
LOADING...